A composition and method of treatment of neuromuscular, neuromuscular degenerative, neurodegenerative, autoimmune, developmental, traumatic,
hearing loss related, and / or metabolic diseases, including
spinal muscular atrophy (SMA) syndrome (SMA1, SMA2, SMA3, and SMA4, also called Type I, II, III and IV),
traumatic brain injury (TBI),
concussion,
keratoconjunctivitis sicca (Dry
Eye Disease),
glaucoma, Sjogren'
s syndrome,
rheumatoid arthritis, post-
LASIK surgery, anti-depressants use, Wolfram Syndrome, and Wolcott-Rallison syndrome. The composition is selected from the group consisting of 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP, bipartite 2,3-
dinitrophenol, 2,4-
dinitrophenol, 2,5-
dinitrophenol, 2,6-dinitrophenol, 3,4-dinitrophenol, or 3,5-dinitrophenol (2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP) prodrugs; Gemini prodrugs, bioprecursor molecules, and combinations thereof. A
dose of the composition for treatment of neurodegenerative diseases may be from about 0.01 mg / kg of
body weight to about 50 mg / kg of
body weight of the patient in need of treatment. A
dose of the composition for treatment of metabolic diseases may be from about 1 mg / 70 kg of
body weight to about 100 mg / 70 kg of body weight of the patient in need of treatment, and a
maximum dose per day is about 200 mg / 70 kg of body weight of the patient in need of treatment.